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Abstract: Lipids and inflammation regulate each other. Early studies on this topic focused on the
systemic effects that the acute inflammatory response—and interleukins—had on lipid metabolism.
Today, in the era of the obesity epidemic, whose primary complications are cardio-metabolic diseases,
attention has moved to the effects that the nutritional environment and lipid derangements have
on peripheral tissues, where lipotoxicity leads to organ damage through an imbalance of chronic
inflammatory responses. After an overview of the effects that acute inflammation has on the systemic
lipid metabolism, this review will describe the lipid-induced immune responses that take place in
peripheral tissues and lead to chronic cardio-metabolic diseases. Moreover, the anti-inflammatory
effects of lipid lowering drugs, as well as the possibility of using anti-inflammatory agents against
cardio-metabolic diseases, will be discussed.
Keywords: lipid; innate immune system; interleukin; lipotoxicity; cholesterol; triglyceride; free
fatty acids
1. Introduction
It has been argued that lipid metabolism and immune system responses cannot be separated in
real life, they regulate each other, and both are part of a virtuous or vicious cycle/response taking place
in the host [1]. This review will describe the interplay between these two systems, whose mediators
are lipoproteins (as well as other products such as free fatty acids and lipokines) and interleukins.
The term “lipids” refers to lipoproteins, which are circulating macromolecules that transport
cholesterol and triglycerides to peripheral tissues. They consist of lipids (triglycerides, cholesterol
esters, and free cholesterol) and proteins, called apolipoproteins, which serve as ligands for receptors
and as cofactors for enzymes. Specific lipoproteins differ in terms of lipid core content, the proportion
of lipids, and type of proteins. Therefore, lipid disorders should be evaluated according to the
Friedrickson classification [2], which is based on the pattern of lipoproteins on electrophoresis
or ultracentifugation. However, they are most often indicated as hypercholesterolemia (elevated
low-density lipoproteins (LDL) cholesterol), hypertriglyceridemia (elevated chilomicrons or very-low
density lipoproteins (VLDL) cholesterol), and/or high-density lipoproteins (HDL) cholesterol,
which are also the most common lipid disorders. The overview on lipoprotein metabolism is
represented in Figure 1.
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Figure 1. Lipoprotein metabolism. Lipoproteins are classified on the basis of their density as 
chylomicrons, VLDL, LDL, and HDL. Chylomicrons are low-density lipoproteins that transport 
dietary lipids from intestinal mucosa to the blood via lymphatic tissue. The associated 
apolipoproteins include apoA (I, II, IV); apoB48; apoC (I, II, III), and apoE. VLDL transports primarily 
triglycerides from the liver to the peripheral tissues and its apolipoproteins are apoB100, apoC (I, II; 
III), and apoE. LDL transports cholesterol esters and its apolipoproteins are apoB100. By contrast, 
HDL transports cholesterol from the periphery to the liver and it consists of cholesterol esters and its 
apolipoproteins are apoA (I, II), apoC (I, II, III), and apoE. With respect to the lipoprotein metabolism, 
after a meal, cholesterol is taken up by the enterocytes via the specific transporter Niemann-Pick C1-
Like 1 (NPC1L1). Triglycerides are lipolyzed into free fatty acids (FFA) and taken up either by passive 
diffusion or by specific transporters such as CD36. Then, cholesterol is esterified by cholesterol 
acyltransferase and FFA is either re-esterified into triglycerides or released directly into the 
circulation. Otherwise, cholesterol and triglycerides assemble with apoB48 to form chylomicrons that 
are released into the circulation. There, they are cleaved by lipoprotein lipase (LPL) into FFA, which 
is used as an energy source by peripheral tissues. Chylomicron remnants are cleared by liver uptake, 
through their binding to LDL receptor family members. In parallel, hepatocytes synthesize cholesterol 
and produce VLDL, which contains triglycerides, cholesterol, and apoB100. VLDL is released into the 
circulation, where it undergoes lipolysis to release FFA. This becomes LDL and is ultimately cleared 
away by the hepatic LDL receptor. The reverse cholesterol transport is a process that takes place in 
the periphery and that is mediated by HDL. Excess cholesterol is transferred to lipid-poor apoAI or 
to nascent HDL by the specific transporters ATP-binding cassette (ABCA1) and ATP-binding cassette 
sub-family G member 1 (ABCG1). Next, cholesterol is esterified by lecithin–cholesterol acyltransferase 
(LCAT). Once HDL is formed, it can directly bind to scavenger receptor class B type 1 (SR-BI) on the 
liver and transfer cholesterol. Otherwise, cholesteryl esters can be transferred to apoB lipoproteins by 
cholesteryl ester transfer protein (CEPT), or a small portion of HDL can acquire apoE and bind to LDL 
receptor. 
With respect to interleukins, they are secreted proteins that allow intercellular communication 
among immune system cells, the immune system and bone marrow cells, and the immune system 
and peripheral tissues. Since the initial discovery of monocyte and lymphocyte interleukins (IL-1 and 
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chylo icrons, VLDL, LDL, and HDL. Chylomicrons are low-density lipoproteins that transport dietary
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apoA (I, II, IV); apoB48; apoC (I, II, III), and apoE. VLDL transports primarily triglycerides from
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cholesterol from t e periphery to the liver and it consists of cholesterol esters and its apolipoproteins
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cholesterol. Otherwise, cholesteryl esters can be transferred to apoB lipoproteins by cholesteryl ester
transfer protein (CEPT), or a small portion of HDL can acquire apoE and bind to LDL receptor.
With respect to interleukins, they are secreted proteins that allow intercellular communication
among immune system cells, the immune system and bone marrow cells, and the immune system and
peripheral tissues. Since the initial discovery of monocyte and lymphocyte interleukins (IL-1 and IL-2),
more than 60 interleukins have been characterized, such that the list goes from IL-1 to IL-39, and includes
interferons (IFN) and tumor necrosis factor (TNF) family members. The receptors, functions, and roles
of interleukins have been recently reviewed by Akdis [3]. In addition, interleukins are often grouped
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according to their ability to induce specific T cell differentiation pathways [4]. So far, there are at least
seven types of T cell subset differentiation pathways that have been described [4]. These include Th1,
Th2, Th17, Th9, Th22, TFH, and Treg responses. Among them, Th1 T cells produce IFN-γ and TNF-α,
they activate macrophages and immune responses against intracellular pathogens, while Th2 T cells
produce IL-4, IL-5, IL-9, and IL-13, and they drive humoral and IgE mediated immunity [4].
Although lipids and interleukins might seem to be separate systems, they are tightly connected.
First, lipids have immune functions against pathogens and modulate immune system responses.
Second, interleukins have profound effects on the whole body metabolism, as demonstrated by
Hotamisligil in 1993, who showed that TNF neutralization improved insulin sensitivity. These findings
provided the scientific evidence that immune mediators are metabolic hormones, a concept also known
as immunometabolism [5].
The initial studies that looked at the lipid-interleukin interplay mostly focused on the systemic
effects that interleukins and the acute inflammatory response had on systemic lipid metabolism.
Consistent with the changes of the global burden of disease [6,7], and given that obesity and its
cardio-metabolic complications account for four million deaths globally, scientific attention has
progressively moved to the effects that nutritional environment and lipid derangements have on
peripheral tissues, where lipotoxicity leads to organ damage through chronic inflammatory responses.
In this setting, experimental and clinical studies have demonstrated that IL-1β and IL-18, together with
IL-6, IL-8, and TNF-α are key mediators of lipid-induced cardio-metabolic diseases [8,9], while others,
such as IL-33 [10], seem to be protective and could be used for therapeutic purposes.
Having said that, after an overview of the effects that the acute inflammatory response has on
systemic lipid metabolism, this review will describe the proinflammatory effects that lipids have
on peripheral tissues, leading to atherosclerosis, metabolic syndrome and cardio-metabolic diseases.
Moreover, the anti-inflammatory effects of lipid lowering drugs as well as the possibility of using
anti-inflammatory agents against cardio-metabolic diseases will be discussed.
2. Effects of Acute Inflammation and Interleukins on Lipid Metabolism
The initial studies investigating the relationship between lipids and inflammation focused on the
effects that the acute inflammatory response and interleukins had on systemic lipid metabolism. These
studies showed that, in humans, acute inflammatory conditions and the rise in the circulating levels of
interleukins led to hypertriglyceridemia and hypocholesterolemia [11].
In particular, these studies, which were based on the administration of lipopolysaccharide
(LPS) and several interleukins at doses mimicking an acute phase response, showed that
hypertrygliceridemia was an early and consistent metabolic alteration taking place in all species
during infection/acute inflammation [12,13]. In this setting, the mechanisms underlying VLDL increase
included the stimulation of VLDL production, due to both increased hepatic fatty acid synthesis and
adipose tissue lipolysis, as well as an impaired VLDL clearance [13]. These effects were obtained by
injecting LPS as well as several interleukins, such as TNF [14], whose infusion increased triglyceride
levels in both animals [15] and humans [16]. As before, the mechanisms underlying TNF-induced
triglyceride increase included not only the inhibition of LPL activity, but also the stimulation of hepatic
lipid secretion [17–20]. Further studies demonstrated that IL-1, IL-2, and IL-6 had similar effects [21],
while IL-4 had no effect on hepatic fatty acid synthesis and it actually inhibited IL-1 and IL-6 effects on
hepatic lipogenesis [22].
By contrast to triglycerides, these studies showed that cholesterol tended to decrease during
an infection/inflammation [12]. This was ascribed to the effects that inflammation and LPS had on
cholesterol biosynthesis, as LPS reduced the activity of the enzyme squalene synthase, which is an
enzyme necessary for cholesterol biosynthesis. Generally, inhibition of squalene synthase causes a
fall in the downstream levels of squalene and cholesterol and an increase in the upstream levels of
mevalonate metabolites, which are redirected into other non-sterol pathways [23]. Moreover, infection
and/or inflammation reduce apoB secretion, which further decreases serum cholesterol [12].
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Interestingly, Feingold et al. put forward that the lipoprotein increase and the lipid changes that
were seen during an acute inflammatory response might represent a protective nonspecific immune
response—elicited by interleukins—that could decrease the toxicity of harmful biological and chemical
agents [11]. Consistent with this view, other studies demonstrated that lipoproteins could bind to
endotoxin and that this binding was protective against its deleterious effects [24,25]. In addition, it was
also found that lipoproteins could bind to several viruses and reduce their toxic effects [26]. Of note,
all these findings are in line with the concept that malnutrition impairs the survival of patients with
acute infections [27].
3. Effects of Cholesterol on the Innate Immune System and Its Interleukins
3.1. Hypercholesterolemia, Inflammation, and Atherosclerosis
Today, moving from infection and malnutrition to overnutrition and cardio-metabolic diseases,
the scientific attention has shifted to the effects that hyperlipidemias, such as hypercholesterolemia
and hypertriglyceridemia, have on tissue inflammation and chronic cardio-metabolic diseases.
Hypercholesterolemia is associated with the accumulation of LDL in the bloodstream. This condition
is very often the result of genetic and environmental factors, like polygenic hypercholesterolemia, but it
can also be due to specific genetic disorders, like familial hypercholesterolemia (FH). The first description
of FH dates back to 1938, when it was noted that families transmitted hypercholesterolemia as
an autosomal dominant trait and this was associated with a dramatic increase in the incidence of
cardiovascular disease (CVD) [28]. Then, in 1973, Goldstein and Brown discovered that FH was
due to a genetic defect of the LDL receptor (LDLR), resulting in an abnormally low uptake of LDL
by the liver [28]. Today, FH is envisioned as a group of related disorders, due to several genetic
defects in addition to LDLR mutation [29]. These genetic defects include gain-of-function mutations
of PCSK9 (proprotein convertase subtilisin/kexin type 9), which is a protein that binds to LDLR and
promotes its degradation; loss-of-function mutations of LDLR adaptor protein, such that LDL fails to be
internalized; as well as mutations in the LDLR-binding domain of apoB100, or ABCG5 (ATP-binding
cassette sub-family G member 5), and ABCG8 (ATP-binding cassette sub-family G member 8) [29].
According to the “lipid hypothesis” [30], cholesterol levels correlate with the risk of CVD
mortality [31], as hypercholesterolemia promotes atherosclerosis development, which is the most
common underlying cause of CVD. Rather than being a merely passive accumulation of cholesterol,
atherosclerosis is an inflammatory disease [32]. Briefly, cholesterol-containing lipoproteins infiltrate
the artery wall, possibly because positive charges on apoB100—as well as apoB48 and apoE—interact
with negative charges of proteoglycans of the extracellular matrix with a subsequent lipoprotein
retention [33,34]. Then, the subendothelial retention of circulating LDL predisposes the lipids to
be oxidized/modified. Once LDL particles are oxidized, they promote endothelial dysfunction,
meaning that the endothelium increases its adhesiveness and permeability, and circulating monocytes
and T cells are recruited [32]. Although initially macrophage recruitment is meant to protect the
vessel by removing modified LDL, when macrophage capacity is overwhelmed, these cells become
overloaded with cholesterol ester droplets, they die, and contribute to the formation of a fatty
streak with a core full of necrotic debris. At this stage, cells release inflammatory interleukins,
chemokines, proteinases, and costimulatory molecules that promote the migration/activation of
vascular smooth muscle cells and other immune cells, such that a fatty streak becomes an advanced
plaque [32]. All mechanisms, whereby the innate and adaptive immune system promote atherosclerosis
development and progression, have been reviewed in detail by Libby and collaborators [35].
One of the links between cholesterol, the immune system, and atherosclerosis development is the
ability that oxidized LDL, modified LDL, and cholesterol crystals have to interact with innate immune
receptors and promote tissue damage (Figure 2). Going back to the attempt of macrophages to limit
plaque formation, the macrophage scavenger receptors that mediate the internalization of LDL particles
include the scavenger receptor A (SR-A), CD36, the macrophage receptor with collagenous structure
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(MARCO), and the lectin-like ox-LDL receptor-1 (LOX1). Interestingly, studies on hypercholesterolemic
mice have provided contradictory results on the exact role of scavenger receptors in atherosclerosis,
possibly because they participate in the process of cholesterol efflux from tissues [36]. By contrast,
experimental studies highlight a major proatherosclerotic role for multiple innate immune receptors
that have been implicated in the recognition of metabolic stimuli/stressors, such as LDL particles, and
the initiation of inflammatory responses in peripheral tissues through IL-1β and IL-18 secretion [9]
(Figure 2). The typical example is represented by toll-like receptors (TLR) [37], which are innate immune
system effectors that are usually required for a host defense against pathogens. The best known is
TLR4, which binds to LPS on the bacterial cell wall and triggers the synthesis of many proinflammatory
proteins [38,39]. Both the endothelium and monocyte-derived macrophages express a broad range of
TLR [40] that can interact with different types of LDL particles. First, oxidized LDL can bind to TLR2
on the vasculature and induce vascular inflammation [41]. Interestingly, in atherosclerosis-susceptible
LDLR-knockout mice, complete deficiency of TLR2 led to a reduction in atherosclerosis. However,
loss of TLR2 expression from bone marrow-derived cells had no effect on disease progression,
indicating that only TLR2 on vasculature is proatherogenic [42]. Second, it has been shown that
modified LDL can bind to TLR4 and promote atherosclerosis [43]. Interestingly, even though TLR4
deficiency reduced atherosclerosis extent, the lack of MyD88, an adaptor protein in the TLR signaling
cascade, further reduced it [44,45], possibly because it participates in the signal-transduction pathway
of the receptors for IL-1β and IL-18 [46,47]. Third, cholesterol crystals can bind to the intracellular
NLRP3 (nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3), which is
another type of immune receptor. This interaction leads to the secretion of IL-1β and IL-18 [48], which
have been associated with atherosclerosis severity [49]. Interestingly, deletion of NLRP3 markedly
reduced the development of aortic lesions in LDLR-knockout mice [50]. Based on this evidence, it is
current scientific opinion that IL-1β and other IL-1 family cytokines are key vascular and systemic
inflammatory mediators that significantly contribute to atherogenesis [8].
It has been argued that the systemic inflammatory response can promote atherosclerosis
development [32]. Consistent with this concept, it has been shown that IL-1β and TNF-α promote
LDL binding to various cell types in vitro [51]. Also C-reactive protein (CRP), which is an acute
phase reactant and a useful biomarker of CVD, might contribute to atherosclerosis development [52].
For instance, it has been demonstrated that CRP binds to oxidized LDL and oxidized phospholipids,
and it promotes their uptake by macrophages [53]. Moreover, recent studies support a causal
role for IL-6 signaling pathway in atherosclerosis [54], which is supported by the evidence that
modulation of the IL-6 pathway associates with reduced cardiovascular events [54]. Moreover,
hypercholesterolemia appears to be associated with systemic inflammation, as assessed by CRP
measurement [55]. For example, patients with homozygous FH exhibit higher levels of CRP, IL-1β,
IL-2R, IL-6, IL-8, IL-10, and TNF-α [56]. Furthermore, these proinflammatory changes in patients with
FH contribute to endothelial dysfunction and atherosclerosis development independent of cholesterol
levels [57]. Interestingly, hypercholesterolemia seems also associated with the expansion of circulating
monocytes and neutrophils [58], increased migratory capacity [59], and several works indicate that
hypercholesterolemia promotes the proliferation and mobilization of hematopoietic stem cells, as well
as extramedullary hematopoiesis [60].
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Figure 2. Interaction between lipids and innate immune receptors. Some lipid products, such as 
oxidized and modified LDL, cholesterol crystals, and ceramides activate innate immune receptors, 
such as TLR and NLRP3. FFA activate NLRP3, but not TLR. However, TLR-activation is a prerequisite 
for FFA to induce inflammation. HMBG1 (High Mobility Group Box 1) and fetuin A mediate TLR4 
activation. Upon ligand binding, TLR trigger the activation JNK (c-Jun N-terminal kinase) and IKKβ 
(inhibitor of nuclear factor kappa-B kinase subunit β), leading to the induction of inflammatory gene 
transcription factors and the expression of proinflammatory cytokines, such as IL-1β and IL-8. NLRP3 
activation leads to the expression of proinflammatory cytokines through the assembly of a large 
multiprotein complex, the inflammasome. The inflammasome consists of the NLRP3 protein, the 
adapter apoptosis-associated speck-like protein, and pro-caspase-1. The NLRP3-inflammasome 
catalyzes the cleavage, activation and secretion of IL-1β and IL-18. Inflammation promotes the 
development of steatosis in the liver, adipose lipolysis, peripheral insulin resistance, leptin resistance 
in the central nervous system, it impairs insulin secretion in the pancreas, and it promotes the 
development and progression of atherosclerosis, leading to obesity, non-alcoholic fatty liver disease 
(NAFLD), type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD). 
3.2. Reduction of Inflammation, LDL, or Both to Protect from Cardiovascular Diseases 
According to the “lipid hypothesis” [30], which suggests that there is a linear relationship 
between cholesterol and the risk of CVD morbidity [31], meaning that cholesterol reduction lowers 
CVD [30], much scientific effort has been put into effective ways to lower blood cholesterol. Statins, 
which are 3-Hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors, are the first-
line drugs for patients with hypercholesterolemia. They inhibit HMGCoA reductase, which is the 
rate-limiting enzyme for cholesterol synthesis, whereby they reduce lipoprotein release from the 
liver. In addition, they upregulate LDLR expression and enhance LDL clearance. Of note, other drugs 
that decrease lipoprotein production by the liver include the apoB antisense oligonucleotide, 
mipomersen, and the microsomal triglyceride transfer inhibitor, lomitapide, which are restricted to 
patients with homozygous FH [61,62]. Alternative treatments include the cholesterol absorption 
inhibitor ezetimibe and the inhibition of PCSK9 [63]. 
In 1994, the Scandinavian Simvastatin Survival Study (4S) demonstrated that giving simvastatin 
to patients with pre-existing coronary artery disease and high LDL significantly decreased 
Figure 2. Interaction between lipids and innate immune receptors. Some lipid products, such as
oxidized and modified LDL, cholesterol crystals, and ceramides activate innate immune receptors,
such as TLR and NLRP3. FFA activate NLRP3, but not TLR. However, TLR-activation is a prerequisite
for FFA to induce inflammation. HMBG1 (High Mobility Group Box 1) and fetuin A mediate TLR4
activation. Upon ligand binding, TLR trigger the activation JNK (c-Jun N-terminal kinase) and IKKβ
(inhibitor of nuclear factor kappa-B kinase subunit β), leading to the induction of inflammatory
gene transcription factors and the expression of proinflammatory cytokines, such as IL-1β and IL-8.
NLRP3 activation leads to the expression of proinflammatory cytokines through the assembly of a
large multiprotein complex, the inflammasome. The inflammasome consists of the NLRP3 protein,
the adapter apoptosis-associated speck-like protein, and pro-caspase-1. The NLRP3-inflammasome
catalyzes the cleavage, activation and secretion of IL-1β and IL-18. Inflammation promotes the
development of steatosis in the liver, adipose lipolysis, peripheral insulin resistance, leptin resistance in
the central nervous system, it impairs insulin secretion in the pancreas, and it promotes the development
and progression of atherosclerosis, leading to obesity, non-alcoholic fatty liver disease (NAFLD), type 2
diabetes mellitus (T2DM) and cardiovascular diseases (CVD).
3.2. Reduction of Inflam ation, LDL, or Both to Protect from Cardiovascular Diseases
According to the “lipid hypothesis” [30], which suggests that there is a linear relationship between
cholesterol and the risk of CVD morbidity [31], meaning that cholesterol reduction lowers CVD [30],
much scientific effort has been put into effective ways to lo er blood cholesterol. Statins, which
are 3-Hydroxy-3-methylglutar lcoenzyme A (HMG-CoA) reductase inhibitors, are the first-line
drugs for patients with hypercholesterolemia. They inhibit HMGCoA reductase, which is the
rate-limiting enzyme for cholesterol synthesis, whereby they reduce lipoprotein release from the
liver. In addition, t e re late L LR expression and enhance LDL clearance. Of n te, other
drugs that decrease lip protein production by the liver i cl e t e apoB antisense oligonucleotide,
mipomersen, and the microsomal triglyceride transfer i i it r, l ita i e, ic are restricted
to patients it z s [61,62]. Alternative treatments include the cholesterol absorption
inhibitor ezetimibe and the inhibition of PCSK9 [63].
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In 1994, the Scandinavian Simvastatin Survival Study (4S) demonstrated that giving simvastatin to
patients with pre-existing coronary artery disease and high LDL significantly decreased cardiovascular
and total mortality rates, providing compelling evidence of the benefit of cholesterol reduction [64].
After the 4S study, other interventional studies have clearly demonstrated that statins safely reduce
CVD morbidity and mortality in high-risk patients in primary and secondary prevention, irrespective
of initial LDL [65]. Today, based on the evidence that cholesterol levels correlate with the risk of
coronary heart disease mortality [31], target levels are defined as those associated with minimal
cardiovascular risk rather than population averages. By contrast, controversies exist regarding the
association between triglycerides and CVD, as triglyceride levels are not independently associated
with coronary mortality [66]. Nevertheless, lowering triglyceride levels <200 mg/dL ameliorates
atherosclerotic disease in patients with well-controlled LDL [67]. Thus, triglycerides should be less
than 150 mg/dL [68,69]. Having said that, with respect to cholesterol, guidelines recommend that total
cholesterol should be less than 200 mg/dL in the general population. In addition, after stratifying
the population according to their cardiac risk, guidelines recommend that LDL should be less than
130 mg/dL in low risk patients, less than 115 mg/dL in moderate risk patients, less than 100 mg/dL in
high risk patients, and less than 70 mg/dL in very high risk patients.
In 2008, the JUPITER trial demonstrated that in healthy people without lipid abnormalities
but with elevated CRP levels, rosuvastatin significantly reduced inflammation and the incidence of
cardiovascular events [70]. These results raised the question as to whether the clinical benefits of statin
treatment were due to LDL, inflammation, or the reduction of both. As matter of fact, statins have direct
anti-inflammatory effects, which have been ascribed to the interaction with several cellular targets,
including small G proteins, such as Ras, Rac, and Rho [71], as well as the promotion of the expression of
antiatherosclerotic molecules [72]. In addition, the JUPITER trial speculated that lowering inflammation
could lower CVD, independent of cholesterol levels. To test this hypothesis, two interventional studies
have been recently designed [73]. The first one, called Canakinumab Anti-inflammatory Thrombosis
Outcomes Study (CANTOS) demonstrated that canakinumab, a monoclonal antibody against IL-1β,
significantly reduced CVD in the absence of lipid lowering effects [74], possibly by modulating the
IL-6 signaling pathway [54]. As a proof-of-concept study supporting the inflammatory hypothesis
of atherosclerosis, the CANTOS study has been a success. Nevertheless, given that the group of
patients treated with canakinumab had a higher—although not statistically significant—incidence
of fatal infections, other therapeutic agents/strategies and more realistic choices are needed [65].
Meanwhile, the second interventional study, the Cardiovascular Inflammation Reduction Trial (CIRT),
which evaluates whether methotrexate will reduce CVD, is still ongoing [73].
The inhibition of PCKS9 is an alternative therapeutic option for lowering cholesterol in patients
where statin therapy fails. Two recent trials, the FOURIER and the ODYSSEY OUTCOMES trials, have
demonstrated that PCKS9 inhibition significantly reduced the risk of major adverse cardiovascular
events in very high risk patients whose LDL remained elevated despite statin therapy at the maximum
tolerated dose [75,76]. PCSK9 is a protein of 692 amino acids belonging to the proprotein convertase
family, whose major function is LDLR degradation by binding to it both intracellularly and at the cell
surface. Currently, there are two monoclonal antibodies to PCSK (alirocumab and evolocumab) that
are available in clinical practice. They inhibit the interaction between PCSK9 and the LDLR, leading to
an increase in the number of LDLR and ultimately enhancing LDL uptake by the liver [63]. Alternative
ways to inhibit PCSK9 include small interfering RNA (siRNA), vaccines, antisense oligonucleotides,
and small molecule inhibitors [63]. Interestingly, the advantages of PCSK9 inhibition go beyond LDL
level reduction. For example, PCKS9 inhibition reduces lipoprotein(a) (Lp(a)) [77,78], which is similar
to LDL but more atherogenic. In addition, recent studies suggest that PCSK9 inhibition might have
anti-inflammatory effects, independent of LDL cholesterol levels [79]. For instance, Lan and colleagues
showed that PCSK9 affects multiple pathways beyond cholesterol metabolism, such as the cell cycle,
the xenobiotic metabolism, and the inflammation and stress response pathways [80]. Interestingly,
when PCSK9-knockout mice were injected with LPS they exhibited a blunted inflammatory response,
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as the levels of TNF-α and IL-6, as well as other mediators, were significantly lower as compared to
wild-type mice [81]. Although PCSK9 is mainly expressed by the liver, it can be found in extrahepatic
tissues too, like in the vasculature, such as in endothelial cells, vascular smooth muscle cells,
and monocytes/macropahges [79]. At a tissue level, PCSK9 deficiency significantly reduced LOX-1
(Lectin-like oxidized LDL receptor-1) expression [82]. Moreover, consistent with a proatherosclerotic
role for PCKS9 independent of lipid levels, PCKS9 overexpression accelerated atherosclerosis in
apoE-knockout mice without significantly affecting plasma lipid levels [83], while gene inactivation
significantly reduced it [84].
3.3. The Lipid Paradox
An observation that challenges the lipid-inflammation paradigm is the fact that patients with some
inflammatory diseases, such as rheumatoid arthritis (RA), may exhibit a fall in LDL cholesterol, but they
still have an increased CVD risk [85]. An explanation for this lipid paradox is that chronic low-grade
inflammation has effects on the cardiovascular system that are independent of lipid levels, consistent
with the JUPITER and CANTOS studies. Another explanation is that inflammation promotes some
changes of the composition/quality of lipoproteins subfractions, ultimately promoting atherosclerosis
development. For example, TNF-α and IL-6 promote the oxidation and the uptake of oxidized LDL
by macrophages, favoring their transformation into foam cells [86]. In addition, patients with RA
exhibit higher levels of small dense LDL particles that cross the endothelium more easily and are
more prone to oxidative changes [87,88], as well as higher levels of Lp(a) [89]. Conversely, serum
levels of protective small HDL are diminished [87]. Consistent with the lipid paradox, patients with
RA who were treated with anti-TNF-α therapy exhibited a 10% increase in total cholesterol and a 7%
increase in HDL within 6 months of TNF-α blockade [90]. However, the same TNF-α blockade has
been associated with substantial morbidity and mortality benefit [91,92]. To reconcile these findings,
it has been argued that TNF-α inhibition changes the quality of lipoproteins, as it ameliorates the
antioxidative capacity of HDL regardless of their concentrations [93], and it leads to a dose-dependent
reduction in serum Lp(a) [94].
3.4. A Defective Cholesterol Biosynthesis Triggers Inflammation
Another observation that challenges the lipid-inflammation paradigm is that patients with defective
cholesterol biosynthesis suffer from central nervous system disorders due to neuroinflammation. As a
foreword to these disorders, it must be said that hypocholesterolemia is generally secondary to
systemic diseases and one of its most common causes is sepsis (due to the mechanisms described in the
first part of the review). Several works have reported that critically ill patients and/or patients
with sepsis, exhibit low cholesterol and LDL values, which are inversely related to circulating
interleukins, such as IL-2, IL-6 and IL-10 [95,96]. Less frequently, hypocholesterolemia is due to
genetic disorders, and it is a rare occurrence, with the exception of familial hypobetalipoproteinemia.
Familial hypobetalipoproteinemia is defined as apoB and LDL levels below the 5th percentile and
seems to be due to several defects, including loss-of-function mutations of PCSK9 and/or mutations
leading to truncation of apoB. Other primary forms include abetalipoproteinemia, characterized by
a virtual absence of apoB-containing lipoproteins, the Anderson disease, or chylomicron retention
syndrome, and combined familial hypolipidemia, which is due to a mutation of the gene for the
angiopoietin-like 3 (ANGPTL3) protein. In addition to these forms of “systemic” hypocholesterolemia,
there can be “tissue” hypocholesterolemias, such as in patients with inherited defects in cholesterol
biosynthesis [97], where circulating cholesterol is normal or slightly low but brain cholesterol can
be virtually absent. This is due to the fact that all the cholesterol contained in the brain is the result
of an in situ synthesis because the blood-brain barrier does not allow the passage of circulating
lipoproteins [98–100]. Therefore, when there is a defect in cholesterol biosynthesis and cholesterol
synthesis is impaired, intermediate metabolites accumulate in the central nervous system and cause
apoptosis, autophagy, and NLRP3-inflammasome activation [97,100–102] (Figure 3), leading to
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neuroinflammation [98,99,103]. The damage to the central nervous system presents with psychomotor
retardation, developmental delay, structural brain malformations, multiple congenital anomalies,
microcephaly, autism and other behavioral disorders [97].Int. J. Mol. Sci. 2018, 19, x 9 of 24 
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4. Effects of Triglycerides on the Innate Immune System and Its Interleukins
4.1. Hypertriglyceridemia: A Case for a Proinflammatory Condition
Not only hypercholesterolemia, but also primary isolated hypertriglyceridemia has been
associated with systemic inflammation. Hypertriglyceridemia results from the accumulation of
triglyceride-rich lipoproteins (e.g., VLDL, VLDL remnants, and chylomicrons) in the bloodstream.
This condition is very often the result of genetic and environmental factors but it can result
also from specific genetic disorders, like hypertriglyceridemia, familial combined hyperlipidemia,
familial dysbetalipoproteinemia, and familial chylomicronemia [104]. Nevertheless, 33% of the adult
population is estimated to have serum triglycerides higher than 150 mg/dL, and this percentage
increases in the subjects aged 60 years or older [105].
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In particular, several reports have shown that patients with isolated hypertriglyceridemia had
increased CRP concentration [106,107]. This was associated with high levels of IL-6 [106,107], which
seems to be the single most important factor controlling the hepatic acute-phase response [108].
Other works have reported an association between hypertriglyceridemia and IL-8, MCP-1,
and TNF-α [106,109]. This association has been known for a long time and it can be ascribed to
the fact that triglyceride-rich lipoproteins seem to be proinflammatory [110]. In particular, one of the
events whereby triglycerides might induce tissue inflammation is the lipolysis that takes place in the
postprandial state, when triglycerides release FFA. It has been shown that there is a 10-fold increase in
FFA concentration when triglycerides are incubated with lipoprotein lipase (LPL) [111], and that FFA
induce endothelial proinflammatory changes, as assessed by TNF-α and ICAM production, as well
as reactive oxygen species formation in cultured endothelial cells [112]. Consistent with the effects
that postprandial lipoproteins might have on the vasculature [113], it has been recently shown that
also fasting triglycerides, which are used as a predictor of the postprandial levels, are independent
predictors of atherosclerosis and cardiovascular events [114,115].
4.2. Free Fatty Acids, Tissue Inflammation, Metabolic Changes
In 1993, the landmark study by Hotamisligil and Spiegelman demonstrated that TNF-α
neutralization ameliorated the peripheral response to insulin, linking inflammation to metabolism [116].
Saturated FFA (such as palmitic acid) have emerged as one of the connectors between
hypertriglyceridemia, chronic tissue inflammation and metabolic disturbances. FFA can trigger
inflammation on several peripheral tissues. For instance, palmitate increased myocyte [117] and
adipocyte [118] expression of IL-6, TNF-α, and we have recently reported that palmitate increased
CXCL8 and TNF-α on hepatocytes [119]. Most importantly, experimental evidence shows that it is
through tissue inflammation that FFA promote insulin resistance in peripheral tissues, such as skeletal
muscle [120] and adipose tissue [121]. For example, the inhibition of skeletal muscle nuclear factor
kappa-B (NF-κB) activation prevented FFA-induced insulin resistance [120]. Likewise, the knockdown
of stress/inflammatory kinases c-Jun N-terminal kinase (JNK) and inhibitor of NF-κB kinase subunit β
(IKKβ) prevented FFA-induced insulin resistance in adipocytes [121]. Interestingly, FFA can trigger an
inflammation also on other tissues, such as endothelial cells [122], vascular smooth muscle cells [123]
and/or circulating monocytes [124].
Similar to what concerns the uptake of cholesterol in the vasculature, studies on the specific FFA
receptors, which include CD36 and fatty acid transport protein (FATP1), have provided contradictory
results on their exact role in tissue inflammation and metabolic changes. Both their upregulation and
deficiency may cause tissue damage by disrupting homeostasis [125–127]. By contrast, several innate
immune receptors have been implicated in the response to FFA, and in the initiation of proinflammatory
changes in peripheral metabolic tissues [9] (Figure 2). Again, these innate immune receptors include
TLR as well as nucleotide-binding oligomerization domain receptors (NOD1/2) and NLRP3. Among
them, TLR are the best characterized family of receptors. They regulate the innate immune system
response by activating proinflammatory signaling pathways in response to microbial pathogens [37].
The hypothesis that FFA could activate TLR4 relied on the observation that saturated FFA was
necessary for LPS-induced inflammation [128,129]. Further studies have led to the current view
that different pathogens—as well as danger—associated molecular patterns (PAMPs or DAMPs)
can induce inflammatory reactions on macrophages and other immune cells, by binding to these
pattern recognition receptors (such as TLR, NOD and NLRP3), with subsequent release of IL-1β and
IL-18 [9]. Interestingly, it has been clarified that palmitate is not an agonist for TLR4 and it does not
activate TLR signaling. However, TLR activation is crucial for FFA-induced inflammation, because
TLR priming leads to a metabolic reprogramming that promotes palmitate-induced inflammatory
changes [130]. Interestingly, unsaturated FFA inhibit saturated FFA-induced proinflammtory
effects [131]. Furthermore, the binding of NLRP3 to FFA or to unsaturated/omega-3 fatty acids
has opposite effects, which are proinflammatory in the first and anti-inflammatory in the second
Int. J. Mol. Sci. 2018, 19, 4058 11 of 24
case [132]. Anyhow, other lipoprotein components/products can bind to innate immune receptors
and triggers proinflammatory responses, such as apoCIII that can interact with TLR2 and activate
circulating monocytes [133].
Given that TLR4 is expressed ubiquitously, TLR4 has emerged as an important mediator of
metabolic inflammation [37]. For example, Shi et al. have been one of the first to demonstrate that
FFA activated TLR signaling on adipocytes, with subsequent release of IL-6 and TNF-α, and that mice
lacking TLR4 displayed lower expression of proinflammatory molecules and greater insulin sensitivity,
when fed with a high-fat diet [134]. Further works have consistently shown that TLR4 deficiency
reduced inflammation, as well as insulin resistance, and hepatic steatosis in response to a high-fat
diet [135–139]. Interestingly, it has been proposed that TLR4 could directly influence adipose tissue
macrophage polarization, which could be a mechanism promoting adipose tissue changes in obese
patients [124,139]. Emerging evidence has revealed that obesity and diabetes increase TLR expression,
promoting tissue inflammation [140]. For example, Jialal et al. have found that TLR tissue expression
increases in diabetic patients [141,142], possibly induced by hyperglycemia [143], and that FFA amplifie
monocyte inflammation in high glucose conditions [144], which could justify hyperglycemia-induced
inflammation. Consistent with this data, human and animal studies show that obesity and insulin
resistance are associated with increased NLRP3 expression in the adipose tissue [132].
4.3. Hypertriglyceridemia is a Feature of the Metabolic Syndrome
Having said that, although hypertriglyceridemia can be an isolated occurrence, it is very often
secondary to obesity and diabetes mellitus. With respect to obesity, the mechanisms leading to
hypertriglyceridemia in patients with diet-induced obesity include increased secretion and severely
impaired clearance of triglyceride-rich particles [145]. It has been demonstrated that in obese subjects
without overt hyperlipidaemia, chylomicron catabolism is impaired [146], and these patients display a
combination of overproduction of VLDL-apoB particles and decreased catabolism of apoB containing
particles in patients with visceral obesity [147]. With respect to diabetes, given that insulin stimulates
LPL activity and inhibits hormone-sensitive lipase in the adipose tissue, circulating chylomicrons
increase as well as the amount of FFA that are released by the adipose tissue, which facilitate hepatic
VLDL production [148]. Moreover, obesity and diabetes are often associated with chronic low-grade
inflammation in peripheral tissues, which impairs lipid metabolism, and activates immune responses,
in the setting of the so-called metabolic syndrome [149].
The metabolic syndrome is a condition where obesity is associated with a chronic low-grade
inflammation, which leads to impaired fasting glucose or type 2 diabetes, hypertryglyceridemia,
low HDL cholesterol, hypertension, [150], as well as non-alcoholic fatty liver disease (NAFLD) and
CVD. The description of NAFLD pathogenesis is beyond the scope of this review and can be found
in a recent review by [151]. Today, the metabolic syndrome is one of the most common metabolic
disturbances affecting 20–25% of the world’s population [150]. With respect to metabolic syndrome
development, it is current scientific opinion that in obesity, the capacity of the adipose tissue to expand
is overwhelmed by overnutrition. Adipocytes increase both in size and number, and this leads to local
hypoxia, adipocyte death, and local inflammation [152] with drastic changes in the resident immune
cell profile and function. Specifically, obese mice and humans accumulate macrophages in their adipose
tissue, proportionally with the increase of their body mass index [153,154]. Moreover, macrophages
shift from the anti-inflammatory phenotype of the lean state to the pro-inflammatory phenotype of
obesity. In the lean state, resident adipose tissue macrophages (also called M2 macrophages) together
with Th2 T cells, Treg cells, and eosinophils produce anti-inflammatory cytokines such as IL-4, IL-10,
and IL-13 [155], which maintain insulin sensitivity. As compared to the lean state, obesity promotes
macrophage recruitment, as well as their shift from M2 to the harmful M1 macrophage phenotype [156].
This shift leads to a relative decrease of anti-inflammatory IL-4, IL-10, and IL-13 and to an increased
production of TNF-α, IL-1β, IL-6 in the adipose tissue, which altogether promote tissue and systemic
inflammation and insulin resistance [157]. The rationale and the results of targeting inflammation in
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the treatment of diabetes are discussed by Donath in Reference [158]. Moreover, proinflammatory
cytokines such as TNF-α regulate lipid metabolism in adipocytes via increasing lipolysis and FFA
release [159].
Not surprisingly, a great number of experimental and clinical studies have shown that metabolic
syndrome is directly associated with circulating IL-6, TNF-α, and CRP [160–162], and that it is inversely
correlated with IL-10 levels [163]. In addition, it has been demonstrated that circulating IL-6 is
associated with body fat and insulin resistance [164,165]. Consistent with these findings, we reported
that experimental models, such as the high-fat diet-fed mouse, as well as patients with metabolic
syndrome displayed a significant increase of circulating IL-6 and CRP [119,122,166,167], and that
the high-fat diet milieu was directly implicated in IL-6 changes as shown in vitro experiments [122].
Interestingly, although elevated levels of proinflammatory mediators are thought to be the consequence
rather than the cause of obesity, it has been shown that also the reverse can be true, as subjects with
elevated concentrations of inflammatory markers were more prone to gain weight during the follow-up
of patients recruited for the MONICA study [168].
The concept that cardio-metabolic diseases are due to an imbalance of chronic inflammatory
responses relies on the observation that several Th2 cytokines, such as IL-4, IL-5, and IL-13, which
usually decrease in obesity, are those that generally improve glucose tolerance and insulin sensitivity [169].
As a result, their administration should reverse the metabolic abnormalities induced by overnutrition.
Consistent with this view, the administration of IL-33, which has the ability to induce the production
of Th2 cytokines, such as IL-3, IL-5, and IL-10, reduced the fat mass and adipose tissue hypertrophy in
genetically obese ob/ob mice [10]. This was associated with a reduction of total cholesterol [10]. Overall,
IL-33 effects have been attributed to the recruitment of beige adipocytes in the adipose tissue, a process
known as “beiging” or “browning of fat” that regulates energy expenditure [170].
4.4. Anti-Inflammatory Effects of Triglyceride-Lowering Drugs
In the last decade, it has been shown that the beneficial cardiovascular outcomes of statin therapy
were due not only to the reduction of cholesterol, but also to its anti-inflammatory actions independent
of LDL levels [65]. There are three drug classes that are clinically available for hypertriglyceridemia
treatment—fibrates, niacin, and omega-3 fatty acids [104]. Fibrates (gemfibrozil and fenofibrate) act
via the peroxisome proliferator receptor selective for the alpha receptor (PPARα). They increase FFA
oxidation, increase LPL synthesis, decrease apoCIII, increase apoAI and apoAII, with subsequent
VLDL reduction. Overall, fibrates lower triglycerides by 30–50% and raise HDL by 10–20%. Niacin or
nicotinic acid is a B-complex that inhibits the mobilization of FFA from peripheral tissues in basal
and noradrenaline-stimulated conditions. It decreases triglyceride synthesis and increases apoB
degradation, leading to a reduction of circulating VLDL. Moreover, niacin inhibits HDL catabolism,
leading to a decrease of triglycerides by 10 to 30%, but also an increase of HDL-C by 10 to 40%.
Polyunsaturated omega-3 fatty acids (PUFA), such as eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), seem to promote ApoB degradation and facilitate chylomicron clearance, whereby they
lower triglyceride levels.
All these triglyceride-lowering drugs have shown to protect against CVD, even though the
question as to whether hypertriglyceridemia is an independent risk factor for CVD remains
unresolved [171]. With respect to the trials on the cardiovascular benefits of fibrates, in the Helsinki
Heart Study [172] fibrates (gemfibrozil) significantly reduced cardiovascular events with no differences
in cardiovascular and total mortality. In the Veterans Affairs High-Density Lipoprotein Cholesterol
Intervention Trial (VA-HIT) [173], gemfibrozil significantly reduced nonfatal myocardial infarction, but
did not change mortality rate. Interestingly, in that study, only HDL (and not triglycerides) predicted
cardiovascular events. Then, the Bezafibrate Infarction Prevention Study showed that only in patients
with triglycerides greater than 200 mg/dL, benzafibrate significantly reduced myocardial infarction
and sudden death [174]. Last, the FIELD study demonstrated that fenofibrate significantly reduced
non-fatal myocardial infarction and revascularization with no effects on total and cardiovascular
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mortality [175]. Consistent with these results, a recent meta-analysis has confirmed that fibrates can
reduce the risk of major cardiovascular events, predominantly by prevention of coronary events [176].
With respect to the other lipid-lowering drugs, clinical trials using niacin, alone or in combination,
with other lipid medications, have shown benefits in decreasing cardiovascular event rates and
atherosclerosis [104]. Likewise, also PUFA exhibit cardioprotective effects, as their intake has shown to
reduce the risk of cardiovascular disease in primary [177] and secondary prevention [178,179], as well
as sudden death [180].
To date, it is not clear if the cardiovascular outcomes of triglyceride-lowering drugs are due
to the reduction of lipid, inflammation, or both. Certainly, be it fibrates, niacin, or PUFA, all these
drugs exhibit anti-inflammatory properties. For instance, fenofibrate can inhibit IL-6 expression
in vascular smooth muscle cells and aortic explants [181,182], via a suppression of the NF-κB and
activator protein 1 (AP-1) transcription factors. Moreover, it could inhibit VCAM-1 and MCP-1
expression in endothelial cells [183,184]. Furthermore, niacin displayed anti-inflammatory effects, as
it significantly reduced the expression of fractalkine, MCP-1, RANTES, and iNOS in TNF-α-treated
adipocytes, and it reduced macrophage migration [185]. As for PUFA, they exhibit anti-inflammatory
properties, whereby they improve insulin sensitivity [186]. For instance, they are capable of inhibiting
many aspects of leukocyte trafficking [187] and they inhibit TRL4 activation upon G-protein coupled
receptor 120 (GPR120) binding [186]; they prevent activation of NLRP3 inflammasome in human
monocytes/macrophages [188]; moreover, they can produce anti-inflammatory and inflammation
resolving mediators called resolvins, protectins, and maresins [187]. These findings have shed light on
the complexity of the interaction between nutrients and inflammation, but at the same time, they have
open therapeutic perspectives against metabolic inflammation [37].
4.5. Lipids: Friends or Foes?
The VA-HIT study showed that raising HDL in patients with CVD significantly reduces the
incidence of major coronary events [173]. The mechanisms underlying the benefits of raising
HDL include not only the cholesterol efflux from the periphery to the liver, but also specific
anti-inflammatory effects of HDL. It has been argued that HDL might have actually belonged to
the innate immune system [189]. For instance, HDL is able to bind LPS and inhibit LPS-induced
inflammatory responses [190]. Likewise, HDL can bind to other bacterial products and limit their
toxic effects [191]. Interestingly, recent studies have shown that preincubation of macrophages
with HDL significantly increased the expression of Activating Transcription Factor 3 (ATF3), which
is a negative transcriptor regulator, whereby HDL might prevent the TLR4-mediated activation
of macrophage [192]. Another mechanism underlying HDL effects is its ability to significantly
reduce membrane cholesterol-rich lipid rafts, which are essential for macrophage response to TLR
ligands [193,194]. Consistent with the modulation of macrophage activation, it has been reported
that HDL induced atherosclerosis regression and altered the inflammatory properties of plaque
monocyte-derived cells in apoE-knockout mice [195]. Likewise, apoAI, the major apolipoprotein of
HDL, prevented T-cell activation and proliferation [196].
Recent studies have revealed that also other lipids—called lipokines—matter in the resolution of
inflammation. The paradigm of these protective mediators is represented by the omega-3 fatty acids,
which interact with the lipid sensor GPR120 with subsequent inhibition of TNF-α and TLR4-mediated
inflammation [186]. The observation that a dysfunctional variant of GPR120 is associated with obesity,
highlights the importance of this pathway and the possibility to use GPR120 as a target against
metabolic disturbances [197]. Additional lipokines include the fatty acid palmitoleate [198], which has
the ability to ameliorate atherosclerosis [199], to reverse high-fat diet-induced proinflammatory
macrophage shift [200], and to prevent skeletal muscle insulin resistance [201]. Another bioactive
lipid signal that protects against adipose tissue inflammation and exhibit anti-diabetic properties is
represented by the palmitic acid hydroxyl stearic acids [202,203]. Last, also the cannabinoid receptor
type 2, which binds to monoacylglycerols, triggers an anti-inflammatory signaling cascade.
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5. Conclusions
Lipid metabolism and the immune system are intertwined. In the era of the obesity epidemic,
lipids and interleukins represent key mediators of cardio-metabolic diseases. Basic and clinical studies
continue to remind us of the importance and the complexity of the crosstalk between lipids and
interleukins. Nevertheless, knowledge gaps remain and only a deeper understanding of the crosstalk
between these two systems might allow one to find better targeted anti-inflammatory therapies
against CVD or diabetes. Further studies might discover cytokines with positive metabolic effects, as
well as new lipid mediators with anti-inflammatory effects, which could represent new promising
therapeutic tools.
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